Drug Topics August 2, 2024
Lauren Biscaldi, MS, Managing Editor, Hayden E. Klein

Losing even 5% of body weight can improve comorbid conditions and other health complications for individuals with overweight and obesity.

Although anyone wishing to improve their health through weight loss can benefit from a glucagon-like peptide-1 (GLP-1) receptor agonist medication, individuals with overweight or obesity who have additional complications or comorbid conditions stand to derive the most benefits from GLP-1s or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 dual agonists, according to Robert Kushner, MD, MS.

Kushner is a professor of medicine and medicine education at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. He spoke with Drug Topics ahead of the American Society for Preventive Cardiology Congress on...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article